RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Harbour BioMed has signed a global multi-year license agreement with an unnamed top-ten immunology/immuno-oncology pharma to use Harbour’s HCAb transgenic mouse platform to discover, develop and commercialize biologic therapeutics. The HCAb platform generates novel, fully human heavy chain only antibodies. Harbour says the platform will accelerate the discovery and development of single domain antibodies, bi-specific and multi-specific antibodies, and CAR-Ts. Harbour has R&D sites in Shanghai and Suzhou, business and research operations in Boston, and an antibody platform in Rotterdam.
Source: China Biotoday